Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at University of Colorado Anschutz

Sites in Aurora, CO

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1010
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Colorado Anschutz, Aurora, CO
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within University of Colorado Anschutz, Aurora, CO. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 685–696 of 1,010 matching trials with a site at University of Colorado Anschutz, Aurora, CO.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

NCT06384261
Site status not listed — check the official record
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Cusatuzumab, Venetoclax, Azacitidine
Drug
Lead sponsor
OncoVerity, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
20
States / cities
Gilbert, Arizona • Duarte, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 31, 2026, 1:35 PM EDT
Recruiting Phase 3 Interventional

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

NCT03907046
Status at this site: Recruiting
View directory record Official record
Conditions
Intracerebral Hemorrhage, Atrial Fibrillation
Interventions
Apixaban, Aspirin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
186
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 141 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 31, 2026, 1:35 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

NCT01368588
Site status not listed — check the official record
View directory record Official record
Conditions
Prostate Cancer
Interventions
three-dimensional conformal radiotherapy, intensity modulated radiotherapy, Brachytherapy, Anti-androgen, luteinizing hormone-releasing hormone (LHRH) agonist or antagonist
Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
2,590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2031
U.S. locations
454
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 351 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 31, 2026, 1:35 PM EDT
Active, not recruiting Phase 1 Interventional

Tele-Rehabilitation to Improve Mild Traumatic Brain Injury Recovery and Reduce Subsequent Injury Risk

NCT05594225
Site status not listed — check the official record
View directory record Official record
Conditions
Brain Concussion
Interventions
Virtual Neuromuscular/Dual-Task Training
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 31, 2026, 1:35 PM EDT
Recruiting Not applicable Interventional

Right Ventricular Response to Exercise Among Patients With Chronic Obstructive Pulmonary Disease

NCT07576894
Status at this site: Recruiting
View directory record Official record
Conditions
COPD, Pulmonary Hypertension, Exercise, Right Ventricular (RV) Dysfunction, Exercise Training
Interventions
Exercise training
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 31, 2026, 1:35 PM EDT
Recruiting Not applicable Interventional

Phenotyping Resting and Exertional Right Ventricular Dysfunction Among Patients With Chronic Obstructive Pulmonary Disease

NCT05896579
Status at this site: Recruiting
View directory record Official record
Conditions
COPD, Pulmonary Hypertension, Right Ventricular Dysfunction, Exercise, Exercise Training
Interventions
Exercise
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 31, 2026, 1:35 PM EDT
Active, not recruiting Not applicable Interventional Results available

Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients

NCT02701283
Site status not listed — check the official record
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
Medtronic Transcatheter Aortic Valve Replacement Systems, Surgical Aortic Valve Replacement (SAVR)
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
Not listed
Enrollment
2,223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
61
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 53 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 31, 2026, 1:35 PM EDT
Recruiting No phase listed Observational

Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)

NCT04635891
Status at this site: Recruiting
View directory record Official record
Conditions
FSHD
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
16
States / cities
Los Angeles, California • Stanford, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 31, 2026, 1:35 PM EDT
Recruiting Phase 2 Interventional

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

NCT01042379
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
Interventions
Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2031
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 31, 2026, 1:35 PM EDT
Active, not recruiting No phase listed Observational

International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry

NCT04496687
Site status not listed — check the official record
View directory record Official record
Conditions
Spontaneous Coronary Artery Dissection
Interventions
Not listed
Lead sponsor
SCAD Alliance
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
30
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 31, 2026, 1:35 PM EDT
Recruiting Phase 2 Interventional

Corticosteroids for Post-Extubation Dysphagia

NCT06670521
Status at this site: Recruiting
View directory record Official record
Conditions
Dysphagia, Laryngeal Edema
Interventions
Methylprednisolone, Normal Saline
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 31, 2026, 1:35 PM EDT
Recruiting Phase 3 Interventional

Neoadjuvant Darovasertib in Primary Uveal Melanoma

NCT07015190
Status at this site: Recruiting
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Darovasertib, Primary Local Therapy
Drug · Procedure
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
35
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 31, 2026, 1:35 PM EDT

About this University of Colorado Anschutz institution page

What this page lists
ClinicalTrials.gov records that list University of Colorado Anschutz in Aurora, CO as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.